We love stocks for companies in healthcare sector, both in biotech and medical appliances industries, especially if these companies develop or already marketing their innovative products. Your investment here, particularly at early stages, not just helps increasing the companies’ financial flexibility for developing a new world-shattering drug and/or revolutionary medical device, but also offers the enormous ROI (return on investment) back to you.
And that exactly the reason why we previously brought to your attention the MRI Interventions (MRIC) which presented over 300% in ROI to our subscribers and Sunshine Heart (SSH), that offered more than 200% ROI in incredibly short-time frame. Our recently profiled company, Lpath, Inc. (LPTN), with its plan for renewal of Phase 2 clinical trials in early August, will follow the same winning pattern.
Healthcare sector securities were, are and always will be explosive, no doubts about them. Don’t stick just for this segment – lots of companies in other market sectors offer astonishing money-making opportunities for the sophisticated investors.
Now:
On Sunday evening we will send research on a small company that operates in industry of defense products/services. This company develops systems for safety and security based on its unique patented technologies. Company sells its products directly in the United States and internationally through a network of independent and specialized distributors. Only this company offered a product that detects and vapors explosives particulates even without physical contact. Intrigued already? The last drop before your curiosity cup run over: company expects a milestone approval in a few weeks ahead that should triple its market valuation.
Enough for now – please check your inbox Sunday evening and join us Monday on this adventure.
An affiliate of PennyStockHaven.com receives up to fifteen thousand dollars per month for consulting and advisory services related to MRI Interventions, Sunshine Heart, Lpath. Our relationship with this affiliate constitutes a conflict and may affect the objectivity of our profile of the company. You should do your own homework and consult an investment professional before making any investment decisions. Read our full disclaimer here.